30-Jan-2025
No headlines found.
Globe Newswire (Wed, 8-Jan 7:00 AM ET)
Globe Newswire (Mon, 6-Jan 8:00 AM ET)
Globe Newswire (Mon, 2-Dec 4:30 PM ET)
Jasper Therapeutics to Participate at Upcoming Investor Conferences
Globe Newswire (Wed, 13-Nov 4:30 PM ET)
Jasper Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Globe Newswire (Thu, 7-Nov 7:30 AM ET)
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.
Jasper Therapeutics - Class A trades on the NASDAQ stock market under the symbol JSPR.
As of January 30, 2025, JSPR stock price climbed to $6.70 with 1,072,498 million shares trading.
JSPR has a beta of 4.19, meaning it tends to be more sensitive to market movements. JSPR has a correlation of 0.14 to the broad based SPY ETF.
JSPR has a market cap of $100.51 million. This is considered a Micro Cap stock.
In the last 3 years, JSPR traded as high as $58.10 and as low as $3.86.
The top ETF exchange traded funds that JSPR belongs to (by Net Assets): VTI, VXF, IWM, VTWO, IWO.
JSPR has underperformed the market in the last year with a return of -42.3%, while the SPY ETF gained +24.7%. In the last 3 month period, JSPR fell short of the market, returning -69.2%, while SPY returned +4.7%. However, in the most recent 2 weeks JSPR has outperformed the stock market by returning +25.5%, while SPY returned +2.3%.
JSPR support price is $5.36 and resistance is $6.20 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that JSPR shares will trade within this expected range on the day.